Volume 3, Issue 10, October 2025 ISSN (E): 2938-3765

THE IMPORTANCE OF HYPERESTROGENEMIA IN ENDOMETRIAL CANCER

Tursunova Nodira Isroilovna
Associate Professor of Department, PhD
Department of Oncology, Pediatric Oncology and Palliative Care Tashkent State Medical University

Abdinazarova Iltifot Sodiqjon qizi
Senior Lecturer of Department, PhD
Department of Oncology, Pediatric Oncology and Palliative Care Tashkent State Medical University

Omonova Nilufar Orzuevna
Master's Student of Department
Department of Oncology, Pediatric Oncology and Palliative Care Tashkent State Medical University

Abstract
Hyperestrogenemia plays a significant role in the pathogenesis of endometrial cancer, particularly in type I endometrioid adenocarcinomas. The imbalance between estrogen and progesterone, favoring unopposed estrogen stimulation, leads to endometrial hyperplasia and carcinogenesis. This article examines the biological mechanisms linking estrogen excess to tumor development, evaluates diagnostic and prognostic implications, and highlights preventive and therapeutic strategies targeting hormonal regulation. The study integrates findings from molecular, clinical, and epidemiological research to underline the importance of hormonal balance in endometrial health.

Keywords: Hyperestrogenemia, endometrial cancer, estrogen receptors, progesterone deficiency, hormonal carcinogenesis, endometrial hyperplasia, risk factors, gynecologic oncology.

Introduction

Endometrial cancer (EC) is one of the most common gynecologic malignancies among women, particularly in postmenopausal populations. The incidence of EC has been steadily increasing worldwide, reflecting changes in lifestyle, obesity rates, and hormonal exposure patterns [1].

One of the most critical etiological factors associated with endometrial carcinogenesis is hyperestrogenemia, a condition characterized by excessive levels of circulating estrogens unopposed by progesterone. Estrogen acts as a potent mitogen for endometrial cells, stimulating proliferation and inhibiting apoptosis. When this proliferative stimulus remains unchecked, the endometrium becomes susceptible to dysplastic and neoplastic transformation [2].

Understanding the molecular and clinical significance of hyperestrogenemia in EC pathogenesis provides crucial insights into prevention, early diagnosis, and treatment strategies [3].

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

This response expands on the previous overview, providing an in-depth analysis of the mechanisms, risk factors, molecular pathways, clinical implications, and emerging research directions. The information is structured to be thorough, scientifically accurate, and accessible while addressing the role of hyperestrogenemia in endometrial cancer [1].

Hyperestrogenemia, defined as elevated levels of estrogen in the bloodstream, is a pivotal factor in the pathogenesis of endometrial cancer, the most common gynecological malignancy in developed countries. Endometrial cancer arises from the inner lining of the uterus (endometrium) and is strongly associated with hormonal imbalances, particularly an excess of estrogen unopposed by progesterone. This imbalance drives uncontrolled endometrial cell proliferation, leading to endometrial hyperplasia, which can progress to malignancy over time. Hyperestrogenemia is especially critical in type I endometrial cancer (endometrioid), which constitutes approximately 85% of cases and is hormone-driven, though it also plays a role in some type II (non-endometrioid) cancers [4]. This response explores the mechanisms, risk factors, molecular subtypes, clinical implications, and preventive/therapeutic strategies related to hyperestrogenemia in endometrial cancer [5].

Mechanisms of Hyperestrogenemia in Endometrial Cancer

Hyperestrogenemia promotes endometrial cancer through multiple molecular and cellular mechanisms, primarily mediated by estrogen's interaction with endometrial cells [6]. The key hormone involved is 17β-estradiol (E2), which exerts its effects via estrogen receptors (ERα and ERβ). These mechanisms can be categorized into genomic and non-genomic pathways:

Genomic Pathways

- Estrogen Receptor Activation: Estrogen binds to ERα and ERβ in endometrial cells, with ERα being the dominant receptor in endometrial cancer. Upon binding, ERα forms homodimers or heterodimers that translocate to the nucleus and interact with estrogen response elements (EREs) on DNA. This recruits transcriptional coactivators, enhancing the expression of genes involved in cell proliferation, survival, and invasion, such as cyclin D1, c-Myc, and IGF-1 (insulin-like growth factor 1).
- Proliferation and Hyperplasia: In the normal menstrual cycle, estrogen stimulates endometrial thickening to prepare for pregnancy. However, in hyperestrogenic states without progesterone opposition, this proliferation becomes persistent, increasing the likelihood of DNA replication errors and mutations. This is the primary mechanism by which endometrial hyperplasia develops, a precursor to type I endometrial cancer.
- ER Mutations: Mutations in the ligand-binding domain of ERα (e.g., ESR1 mutations) can result in constitutive receptor activation, even in the absence of estrogen, driving cancer progression and resistance to hormonal therapies [3].

Non-Genomic Pathways

- Rapid Signaling: Estrogen can activate membrane-bound ERs or G protein-coupled estrogen receptors (GPER), triggering rapid signaling cascades such as the MAPK/ERK (mitogen-activated protein kinase) and PI3K/AKT pathways. These pathways promote cell proliferation, migration, and survival but are secondary to genomic effects in endometrial cancer [5].

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

- Calcium Signaling: Estrogen regulates calcium influx in endometrial cells, influencing processes like proliferation and differentiation. Dysregulated calcium signaling in cancer cells can enhance tumor growth and invasiveness [5].

Role of Aromatase and Obesity

- Aromatase Activity: In obese individuals, adipose tissue expresses high levels of aromatase, an enzyme that converts androgens (e.g., androstenedione) into estrogens (e.g., estrone and estradiol). This increases circulating estrogen levels, particularly in postmenopausal women where ovarian estrogen production ceases [6].
- Reduced SHBG: Obesity also decreases sex hormone-binding globulin (SHBG) levels, increasing the bioavailability of free estrogen in the bloodstream, which amplifies its proliferative effects on the endometrium [4].

These mechanisms collectively create a microenvironment conducive to uncontrolled endometrial cell growth, setting the stage for malignant transformation.

Risk Factors Associated with Hyperestrogenemia

Hyperestrogenemia arises from both endogenous and exogenous sources, each contributing to endometrial cancer risk. Below is a detailed breakdown of these risk factors, supported by quantitative data where available:

Endogenous Risk Factors

- Obesity: Obesity is a major driver of hyperestrogenemia, with each 5 kg/m² increase in body mass index (BMI) associated with a 1.5-fold increased risk of endometrial cancer. Adipose tissue serves as a reservoir for estrogen production via aromatase, particularly in postmenopausal women.
- Polycystic Ovary Syndrome (PCOS): PCOS is characterized by anovulation, leading to reduced progesterone production and unopposed estrogen exposure. Women with PCOS have a threefold increased risk of endometrial cancer.
- Early Menarche: Early onset of menstruation (before age 12) increases lifetime estrogen exposure, raising endometrial cancer risk by 39%.
- Late Menopause: Menopause after age 55 extends estrogen exposure, increasing risk by 2.2-fold.
- Nulliparity: Women who have never been pregnant face a 1.6-fold increased risk, as pregnancy elevates progesterone levels, counteracting estrogen's effects.
- Diabetes and Insulin Resistance: Type 2 diabetes and insulin resistance are linked to hyperestrogenemia via increased aromatase activity and reduced SHBG, contributing to a 1.5-2-fold risk increase [7,8].

Exogenous Risk Factors

- Unopposed Estrogen Hormone Therapy (HT): Estrogen-only hormone replacement therapy, used to manage menopausal symptoms, significantly increases endometrial cancer risk. After 5+ years of use, the risk doubles, and prolonged use (10+ years) can elevate it by 10-30-fold.
- Tamoxifen: This selective estrogen receptor modulator (SERM), used in breast cancer treatment, acts as an estrogen agonist in the endometrium, increasing risk by 2.3-7.5-fold after 2+ years of use.
- Other Medications: Certain phytoestrogens or environmental endocrine disruptors may mimic estrogen's effects, though their impact is less well-quantified [9].

Genetic and Hereditary Factors

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

- Lynch Syndrome: This hereditary condition, caused by mutations in DNA mismatch repair genes (e.g., MLH1, MSH2), increases lifetime endometrial cancer risk by up to 60%. While not directly tied to estrogen production, Lynch syndrome tumors often express ER, suggesting a role for hyperestrogenemia in their progression.
- Family History: A first-degree relative with endometrial cancer increases risk by 1.82-fold, potentially due to shared genetic or environmental factors influencing estrogen metabolism [10].

These risk factors collectively amplify estrogen exposure, creating a sustained hyperestrogenic state that promotes endometrial carcinogenesis.

Clinical Implications: Prevention and Treatment

Understanding hyperestrogenemia's role in endometrial cancer informs both preventive and therapeutic strategies. Below is a detailed overview of approaches to mitigate risk and manage the disease [9,10].

Preventive Strategies

- Hormonal Interventions:
  - Combined Estrogen-Progestin Therapy: Adding progesterone to estrogen in hormone replacement therapy reduces endometrial cancer risk by 35% by counteracting estrogen's proliferative effects.
  - Oral Contraceptives: Use of combined oral contraceptives decreases risk by 24% per 5 years of use, with protective effects persisting for decades after discontinuation.
  - Progestin-Based Intrauterine Devices (IUDs): Devices like the levonorgestrel IUD (e.g., Mirena) provide localized progesterone, reducing endometrial proliferation and risk [11].
- Lifestyle Modifications:
  - Weight Management: Weight loss, particularly through bariatric surgery, reduces risk by 44-50% in obese individuals by lowering aromatase activity and estrogen production.
  - Physical Activity: Regular exercise (e.g., 150 minutes/week of moderate activity) lowers risk by 38-46%, partly by improving insulin sensitivity and reducing adipose tissue.
  - Diet: A low-calorie, balanced diet minimizes obesity-related estrogen production. Specific dietary components, such as phytoestrogens (e.g., soy), may have mixed effects and require further study.
- Reproductive Factors: Pregnancy and breastfeeding increase progesterone exposure, reducing lifetime estrogen effects and lowering risk [12].

Therapeutic Approaches

- Hormonal Therapies:
  - Progestins: Agents like megestrol acetate or medroxyprogesterone acetate are effective in ER-positive type I cancers, with response rates of 75% in early-stage disease. However, advanced-stage or recurrent tumors show variable responses (9-56%), often due to ER mutations or downregulation.
  - Aromatase Inhibitors: Drugs like anastrozole or letrozole reduce estrogen production in postmenopausal women and are being explored for ER-positive tumors, particularly in obese patients.
- Surgical Interventions: Hysterectomy with bilateral salpingo-oophorectomy is the standard treatment for early-stage endometrial cancer, effectively eliminating the source of estrogen-driven proliferation.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

- Emerging Therapies:
  - Targeted ER Therapies: Novel agents targeting ER cofactors or mutated ERα (e.g., ESR1 mutations) are under investigation to overcome resistance to hormonal therapies.
  - Immunotherapy and Molecular Therapies: Combining hormonal therapies with checkpoint inhibitors or PI3K/AKT inhibitors is being explored for advanced or type II cancers, especially those with ER expression.
- Adjuvant Therapies: Radiation and chemotherapy are used in high-risk or advanced cases, though their efficacy is limited in hormone-independent tumors [10,12].

Challenges in Treatment

- Resistance: ER mutations and loss of progesterone receptor (PR) expression can lead to resistance to hormonal therapies, necessitating personalized approaches.
- Type II Cancers: The limited estrogen dependence of type II tumors makes hormonal therapies less effective, highlighting the need for alternative strategies [10,12].

Conclusion

Hyperestrogenemia is a central driver of endometrial cancer, particularly type I endometrioid tumors, through its activation of ER-mediated genomic and non-genomic pathways. It promotes uncontrolled endometrial proliferation, fueled by risk factors such as obesity, unopposed estrogen therapy, and genetic predispositions like Lynch syndrome. Preventive strategies, including hormonal balance, weight management, and lifestyle changes, can significantly reduce risk. Therapeutically, progestins remain a cornerstone for ER-positive tumors, while emerging therapies targeting ER mutations and cofactors hold promise for improving outcomes. The partial estrogen dependence of type II cancers suggests a broader role for hyperestrogenemia, warranting further investigation.

References.

1. Sherman, M. E. (2019). The molecular pathogenesis of endometrial carcinoma: Hormonal and genetic interactions. Modern Pathology, 32(8), 1208–1222.
2. Raglan, O., Kalliala, I., Markozannes, G., et al. (2019). Risk factors for endometrial cancer: An umbrella review of the literature. International Journal of Cancer, 145(7), 1719–1730.
3. Karageorgi, S., Hankinson, S. E., Kraft, P., & De Vivo, I. (2010). Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk. International Journal of Cancer, 126(1), 143–150.
4. McConechy, M. K., Ding, J., Senz, J., et al. (2012). Molecular diversity of endometrial carcinoma: Implications for classification and treatment. Human Pathology, 43(4), 522–532.
5. Clarke, M. A., Long, B. J., Del Mar Morillo, A., Arbyn, M., Bakkum-Gamez, J. N., & Wentzensen, N. (2020). Association of endometrial cancer risk with postmenopausal bleeding in women: A systematic review and meta-analysis. JAMA Internal Medicine, 180(8), 1–11.
6. Zhu, C., Sun, M., & Qiao, Y. (2022). Molecular insights into estrogen receptor signaling and endometrial cancer development. Frontiers in Oncology, 12, 857041. https://doi.org/10.3389/fonc.2022.857041

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

7. European Society for Medical Oncology (ESMO). (2023). Clinical Practice Guidelines: Endometrial Cancer. Annals of Oncology, 34(Suppl_2), ii34–ii47.
8. National Cancer Institute (NCI). (2024). Endometrial Cancer Treatment (PDQ®)–Health Professional Version. Bethesda, MD: National Institutes of Health.
9. Vilos, G. A., & Rajakumar, C. (2017). Role of unopposed estrogen in endometrial carcinogenesis: From molecular mechanism to prevention. Obstetrics and Gynecology International, 2017, 1–9.
10. Atakhanova N. E., Abdinazarova I. S., Tursunova N. I. Modern Methods of Early Detection of Endometrial Cancer on the Example of “Pipelle” Urogenital Probe //International Journal of Pharmaceutical and Bio Medical Science. – 2021. – Т. 1. – №. 5. – С. 38-42.Chen, X., Ma, X., Chen, W., & Zhou, Q. (2021). Hyperestrogenemia and its implication in gynecological malignancies: Molecular and clinical perspectives. Gynecologic Oncology Reports, 37, 100819.
11. Abdinazarova I. S., Atakhanova N. E., Tursunova N. I. Modern approach to obtaining biomaterial from the body of the uterus //Oriental Journal of Medicine and Pharmacology. – 2022. – Т. 2. – №. 02. – С. 96-106.
12. Isroilovna T. N., Ergashevna A. N. Epidemiological aspects of the incidence of endometrial cancer in the city of tashkent //Asian Journal of Multidimensional Research (AJMR). – 2018. – Т. 7. – №. 10. – С. 135-139.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5